Cullinan Therapeutics, Inc. (CGEM) has a negative trailing P/E of -4.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -24.86%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -1.7 | 0.00 | -1.16 | 0.00 | - |
| 2019 | -1.5 | -0.14 | -0.75 | 0.00 | - |
| 2020 | -25.1 | 0.27 | 6.54 | 0.00 | - |
| 2021 | -10.4 | -0.43 | 1.61 | 36.08 | - |
| 2022 | 4.3 | -0.02 | 0.89 | 0.00 | - |
| 2023 | -2.8 | 0.01 | 0.93 | 0.00 | - |
| 2024 | -3.9 | 0.25 | 1.11 | 0.00 | - |
| 2025 | -2.8 | -0.14 | 1.50 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-1.24 | $0.00 | $-14.19M | - |
| 2019 | $-0.46 | $0.00 | $-20.04M | - |
| 2020 | $-1.17 | $0.00 | $-51.8M | - |
| 2021 | $-1.47 | $18.94M | $-65.57M | -346.1% |
| 2022 | $2.38 | $0.00 | $111.21M | - |
| 2023 | $-3.69 | $0.00 | $-153.16M | - |
| 2024 | $-3.11 | $0.00 | $-167.38M | - |
| 2025 | $-3.72 | $0.00 | $-219.88M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.02 | $-3.79 – $-2.05 | $26.68M | $6.93M – $46.44M | 8 |
| 2027 | $-2.84 | $-3.49 – $-2.19 | $34.73M | $6.44M – $58.92M | 7 |
| 2028 | $-2.52 | $-3.24 – $-1.87 | $51.83M | $11.51M – $89.06M | 6 |
| 2029 | $-2.97 | $-5.74 – $0.03 | $69.74M | $15.48M – $119.82M | 4 |
| 2030 | $-0.92 | $-1.79 – $0.01 | $280.69M | $62.31M – $482.26M | 2 |
